Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kura Oncology (KURA) Other Accumulated Expenses (2022 - 2026)

Kura Oncology has reported Other Accumulated Expenses over the past 5 years, most recently at $3.6 million for Q1 2026.

  • Quarterly Other Accumulated Expenses rose 3.18% to $3.6 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $3.6 million through Mar 2026, up 3.18% year-over-year, with the annual reading at $3.4 million for FY2025, 25.17% up from the prior year.
  • Other Accumulated Expenses was $3.6 million for Q1 2026 at Kura Oncology, up from $3.4 million in the prior quarter.
  • Over five years, Other Accumulated Expenses peaked at $6.3 million in Q3 2025 and troughed at $1.3 million in Q4 2023.
  • The 5-year median for Other Accumulated Expenses is $2.6 million (2024), against an average of $3.0 million.
  • Year-over-year, Other Accumulated Expenses crashed 46.55% in 2023 and then soared 154.36% in 2025.
  • A 5-year view of Other Accumulated Expenses shows it stood at $2.4 million in 2022, then tumbled by 46.55% to $1.3 million in 2023, then surged by 108.14% to $2.7 million in 2024, then rose by 25.17% to $3.4 million in 2025, then increased by 6.1% to $3.6 million in 2026.
  • Per Business Quant, the three most recent readings for KURA's Other Accumulated Expenses are $3.6 million (Q1 2026), $3.4 million (Q4 2025), and $6.3 million (Q3 2025).